complement C5
有货
产品名称 | complement C5 |
---|
CAS编号和信息 | rp173718 |
---|
Ligand ID | 8712 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
名称 | complement C5 | ||||||||||
类别 | Peptide | ||||||||||
学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide | ||||||||||
生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
||||||||||
评价 |
This is the full length, pre-pro-protein structure as represented in NCBI Reference Sequence: NP_001726. This peptide is cleaved into the complement C5 beta chain, complement C5 alpha chain and C5a anaphylatoxin (see the UniProt entry for the human protein P01031). C5 inhibition is a clinically validated mechanism that is utilised for the control and suppression of complement-induced hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). SARS-CoV-2 and COVID-19: Clinically approved and investigation candidates that target C5 are being evaluated in a number of clinical trials to determine their potential to combat complement-mediated inflammatory tissue damage in the organs of pateints with severe COVID-19. |
||||||||||
配体家族 | Complement components and ligands | ||||||||||
基因/前体 |
|
||||||||||
单字母多肽序列 | |||||||||||
三字母多肽序列 | |||||||||||
翻译后修饰 | |||||||||||
化学修饰 |
1. Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T et al.. (2014) Genetic variants in C5 and poor response to eculizumab.. N Engl J Med, 370 (7): (632-9). [PMID:24521109] |
2. Fukuzawa T, Sampei Z, Haraya K, Ruike Y, Shida-Kawazoe M, Shimizu Y, Gan SW, Irie M, Tsuboi Y, Tai H et al.. (2017) Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.. Sci Rep, 7 (1): (1080). [PMID:28439081] |